Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$136.63 USD
-1.84 (-1.33%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $136.57 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Neurocrine Biosciences, Inc. has a PEG ratio of 1.30 compared to the Medical - Drugs industry's PEG ratio of 1.38.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NBIX 136.63 -1.84(-1.33%)
Will NBIX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS or NBIX: Which Is the Better Value Stock Right Now?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for NBIX
Is NBIX likely to continue higher? Directional Movement Crossover Bullish shows up after sliding 0.44%
Neurocrine price target raised to $195 from $188 at UBS
Neurocrine price target raised by $7 at UBS, here's why
Is NBIX poised for gains? Crossed Above 50 Day Moving Average shows up after rising 1.52%
UBS Analyst Raises Price Target for Neurocrine Biosciences (NBIX) | NBIX Stock News